<DOC>
	<DOC>NCT02191319</DOC>
	<brief_summary>Collecting data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) after switching from protease inhibitor or NNRTI to Nevirapine (Viramune®) and collecting of routinely observed laboratory data on lipids, and liver enzymes.</brief_summary>
	<brief_title>Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Patients suffer from HIV type 1 infection Patient is treated with antiretroviral proteaseinhibitors or nonnucleoside reverse transcriptase inhibitors Patient has shown a depression of viral load before limit of detection (&lt; 50 HIVRNA copies/ml) for more than 6 months prior to visit 1 Patient is male or female with age greater than or equal to 18 years Women have to be willing to use an effective barrier method of contraception for the duration of the observational study participation Patient has clinically relevant laboratory findings (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; five times upper limit of normal (ULN)) Patients is hypersensitive to Viramune® or to any of its excipients Patient is not able to abstain from treatment with ketoconazole, oral contraceptives, or other drug affecting CYP3Ametabolism Patients is breastfeeding Patient is pregnant Patient is a woman and does not use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>